Aposense Ltd.
Biopharmaceutical company developing a platform technology (molecular nano-motor, MNM) for intracellular delivery of large macromolecules (DNA, RNA, proteins, peptides). Activities span preclinical studies, formulation and GMP clinical manufacturing, regulatory interaction, and Phase I clinical evaluation for an intranasal siRNA therapy.
Industries
N/A
Nr. of Employees
small (1-50)
Aposense Ltd.
Products
MNM intracellular delivery platform
A molecular nano-motor delivery modality designed to transport large molecules across cell membranes and release cargo in the cytoplasm via a cleavable linkage.
Intranasal MNM-siRNA program (SARS-CoV-2)
Intranasal siRNA conjugate program targeting a conserved SARS-CoV-2 gene intended for pre-exposure prophylaxis, post-exposure prophylaxis, and therapeutic use; advanced through a Phase I randomized, placebo-controlled trial.
Preclinical MNM-siRNA programs for respiratory viruses (influenza, RSV)
Preclinical development of intranasal/inhaled siRNA-MNM conjugates targeting conserved viral sites for influenza and RSV.
Preclinical IPF MNM-siRNA program
Anti-idiopathic pulmonary fibrosis program using MNM-siRNA conjugates with proof-of-concept activity observed in a bleomycin-induced mouse model.
Preclinical neurodegenerative siRNA program (intrathecal)
Preclinical work on intrathecal administration of conjugated siRNA for heritable neurological diseases.
Peptide delivery proof-of-concept
Preclinical demonstration that conjugation of the delivery moiety to peptides improves intracellular activity relative to a comparator cell-penetrating peptide, with observed synergistic enhancement when combined.
MNM intracellular delivery platform
A molecular nano-motor delivery modality designed to transport large molecules across cell membranes and release cargo in the cytoplasm via a cleavable linkage.
Intranasal MNM-siRNA program (SARS-CoV-2)
Intranasal siRNA conjugate program targeting a conserved SARS-CoV-2 gene intended for pre-exposure prophylaxis, post-exposure prophylaxis, and therapeutic use; advanced through a Phase I randomized, placebo-controlled trial.
Preclinical MNM-siRNA programs for respiratory viruses (influenza, RSV)
Preclinical development of intranasal/inhaled siRNA-MNM conjugates targeting conserved viral sites for influenza and RSV.
Preclinical IPF MNM-siRNA program
Anti-idiopathic pulmonary fibrosis program using MNM-siRNA conjugates with proof-of-concept activity observed in a bleomycin-induced mouse model.
Preclinical neurodegenerative siRNA program (intrathecal)
Preclinical work on intrathecal administration of conjugated siRNA for heritable neurological diseases.
Peptide delivery proof-of-concept
Preclinical demonstration that conjugation of the delivery moiety to peptides improves intracellular activity relative to a comparator cell-penetrating peptide, with observed synergistic enhancement when combined.
Services
Licensing of intracellular delivery platform and collaborative development with pharmaceutical partners.
Licensing of intracellular delivery platform and collaborative development with pharmaceutical partners.
Expertise Areas
- Intracellular macromolecule delivery
- siRNA therapeutic development
- Intranasal and inhaled respiratory delivery
- Peptide and small-protein intracellular delivery
Key Technologies
- Conjugation chemistry for macromolecule attachment
- siRNA therapeutics
- Intranasal formulation
- Intrathecal delivery approaches
News & Updates
Company attendance at the JP Morgan healthcare conference, January 13-16, 2025.
Announcement of successful completion of a randomized, double-blind, placebo-controlled Phase I trial of an intranasal siRNA therapy targeting SARS-CoV-2; study conducted at Hadassah Clinical Research Center.
Update describing progression of a Phase I clinical trial for an intranasal MNM-siRNA COVID-19 candidate; notes GMP manufacturing and regulatory authorization steps.
Disclosure of a $10.25 million funding round supported by a major foundation and a corporate merger/rebranding event that led to the current company identity.
Completion of a randomized, double-blind, placebo-controlled Phase I trial of an intranasal siRNA therapeutic for SARS-CoV-2, meeting planned milestones.
Raised $10.25 million in a funding round and completed a merger/rebranding event to form the current company entity.
Company attendance at the JP Morgan healthcare conference, January 13-16, 2025.
Announcement of successful completion of a randomized, double-blind, placebo-controlled Phase I trial of an intranasal siRNA therapy targeting SARS-CoV-2; study conducted at Hadassah Clinical Research Center.
Update describing progression of a Phase I clinical trial for an intranasal MNM-siRNA COVID-19 candidate; notes GMP manufacturing and regulatory authorization steps.
Disclosure of a $10.25 million funding round supported by a major foundation and a corporate merger/rebranding event that led to the current company identity.
Completion of a randomized, double-blind, placebo-controlled Phase I trial of an intranasal siRNA therapeutic for SARS-CoV-2, meeting planned milestones.
Raised $10.25 million in a funding round and completed a merger/rebranding event to form the current company entity.